(Q30405733)

21 June 2017

1 reference

title

Safety of pandemic H1N1 vaccines in children and adolescents (English)

1 reference

21 June 2017

0 references

4

Jan Bonhoeffer

1 reference

21 June 2017

5

Miriam Sturkenboom

1 reference

21 June 2017

Leonoor Wijnans

1

1 reference

21 June 2017

Sandra de Bie

series ordinal

2

1 reference

21 June 2017

Jeanne Dieleman

series ordinal

3

1 reference

21 June 2017

language of work or name

English

0 references

publication date

5 August 2011

1 reference

21 June 2017

number of pages

13

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

21 June 2017

volume

29

1 reference

21 June 2017

issue

43

1 reference

21 June 2017

page(s)

7559-7571

1 reference

Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010.

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Lessons learnt from pandemic A(H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Population and risk group uptake of H1N1 influenza vaccine in mainland France 2009–2010: Results of a national vaccination campaign

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Inactivated influenza virus vaccines in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Vaccines for preventing influenza in healthy children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Inactivated influenza vaccine (IIV) in children <2 years of age: examination of selected adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) after thimerosal-free or thimerosal-containing vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Safety and efficacy of live attenuated, cold-adapted, influenza vaccine-trivalent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Safety of the trivalent inactivated influenza vaccine among children: a population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Adverse events reported following live, cold-adapted, intranasal influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Adverse Events Following Trivalent Inactivated Influenza Vaccination in Children: Analysis of the Vaccine Adverse Event Reporting System

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Oculorespiratory syndrome after influenza immunization in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

A novel influenza A (H1N1) vaccine in various age groups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Responses to 2009 H1N1 vaccine in children 3 to 17 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

The development of standardized case definitions and guidelines for adverse events following immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Reporting of vaccine safety data in publications: systematic review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

H1N1 vaccination in pediatric renal transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to [...]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Immunogenicity of inactivated 2009 H1N1 influenza vaccine in pediatric liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Spontaneous reporting of adverse events following immunisation against pandemic influenza in Denmark November 2009-March 2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009–January 31, 2010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Safety and effectiveness of a 2009 H1N1 vaccine in Beijing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

NSW Annual Adverse Events Following Immunisation Report, 2009.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Safety of MF-59 adjuvanted vaccine for pandemic influenza: results of the vaccination campaign in an Italian health district

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Guillain-Barré syndrome following receipt of influenza A (H1N1) 2009 monovalent vaccine in Korea with an emphasis on Brighton Collaboration case definition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Serious adverse reactions should be further monitored after influenza A (H1N1) vaccination among children: postmarketing experience with 570,000 vaccinations between October 2009 and August 2010 in Guangzhou, China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Adverse events associated with pandemic influenza vaccines: comparison of the results of a follow-up study with those coming from spontaneous reporting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Fever following immunization with influenza A (H1N1) vaccine in children: a survey-based study in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Adverse neurologic reactions after both doses of pandemic H1N1 influenza vaccine with optic neuritis and demyelination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Guillain-Barré syndrome following H1N1 immunization in a pediatric patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Bilateral sudden deafness following H1N1 vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Cytophagic histiocytic panniculitis after H1N1 vaccination: a case report and review of the cutaneous side effects of influenza vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Acceptance and adverse events of the 2009 H1N1 vaccination in immunosuppressed pediatric liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Post-H1N1 narcolepsy-cataplexy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

Methodologic reporting requirements for clinical trials: advancing the science today and tomorrow

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.016

10.1016/J.VACCINE.2011.08.016

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference